Article Text

Download PDFPDF
Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab
  1. Islam Osama Nassar,
  2. Jonathan Cheesbrough,
  3. Mohammed Nabil Quraishi,
  4. Naveen Sharma
  1. Gastroenterology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  1. Correspondence to Dr Islam Osama Nassar, Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; islam.nassar{at}


Vedolizumab is a gut-selective monoclonal antibody approved for the management of Crohn’s disease and ulcerative colitis. The available data demonstrate a favourable response to dose escalation in patients with primary non-response or secondary loss of response to vedolizumab. While therapeutic drug monitoring has a proven clinical utility for tumour necrosis factor antagonists, the available guidance for therapeutic drug monitoring and dose escalation of vedolizumab is rather limited. The present review proposes a practical algorithm to use vedolizumab trough levels in the management of treatment failure. Therapeutic drug monitoring can differentiate underexposed patients from those with mechanistic failure. Underdosed patients can respond to dose escalation instead of unnecessarily switching to other treatment modalities. We also review the safety and potential cost-effectiveness of vedolizumab dose escalation, the role of antidrug antibodies and the possible applicability of this strategy to subcutaneous vedolizumab.

  • chronic ulcerative colitis
  • crohn's colitis
  • crohn's disease
  • IBD
  • IBD clinical

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Conceptualisation: ION and NS. Methodology: ION. Data Acquisition: ION. Visualisations: ION. Writing the Manuscript: ION. Critical Review: JC, MNQ and NS. Supervision: NS. All the authors approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Highlights from this issue
    R Mark Beattie